
News|Videos|December 9, 2020
The Most Interesting Results from the RESET Clinical Trial
In an interview with Pharmacy Times, Helen Thackray, MD, reveals what finding she believes was the most interesting after analyzing the results of the RESET clinical trial, which covers the early initiation with rivipansel for acute vaso-occulusive crisis in sickle cell disease.
Advertisement
In an interview with Pharmacy Times, Helen Thackray, MD, reveals what finding she believes was the most interesting after analyzing the results of the RESET clinical trial, which covers the early initiation with rivipansel for acute vaso-occulusive crisis in sickle cell disease. This study was presented at the 62nd ASH Annual Meeting and Exposition.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Cuts MACE Risk in Diabetes With Heart Disease
2
FDA Approves mFlusiva, the First mRNA-Based Influenza Vaccine
3
CVS Health Expands GLP-1 Access With $29 Visits, Lilly Deal
4
The Side Door We Could Close: A Pharmacy Perspective on Menopause, Access, and the Leadership Pipeline
5




































































































